Equity Profile

ROIV

Roivant Sciences Ltd.

Health CareBiotechnology$24.8B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and successfully commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes. Operating in the health care sector, Roivant's work is significant as it aims to address unmet medical needs and enhance drug development efficiency.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the next day.

Management Promises & Guidance

Continue advancing clinical trials for key therapies.
Focus on expanding partnerships and collaborations.
Enhance operational efficiencies to drive profitability.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Roivant has shown strong EPS surprises in recent quarters, but there is uncertainty regarding revenue growth and pipeline updates.

Bull Case

If Roivant continues its trend of beating EPS estimates and provides positive updates on its drug pipeline, investor confidence could rise significantly.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates will Roivant provide regarding its drug pipeline?

The market will closely scrutinize any advancements or setbacks in the pipeline, as these can significantly impact future revenue potential.

How does management plan to achieve profitability in the upcoming quarters?

Investors are eager to hear concrete strategies for improving financial performance, especially in light of recent EPS surprises.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's potential for pipeline advancements, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Roivant has consistently surprised on EPS, indicating stronger operational performance than anticipated.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in biotechnology suggest a favorable environment for innovative therapies.

Key Risk

If the pipeline updates reveal significant progress, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Roivant's ability to leverage its innovative pipeline to drive future growth and profitability.

Bull Confirmed If

A positive update on the drug pipeline with at least one new therapy entering late-stage trials.

Bear Confirmed If

Any indication that key therapies are delayed or facing regulatory challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a nearly 10% move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.3%, with a raw directional average of +2.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations and raises guidance, history suggests a strong positive reaction, averaging a 9.09% increase in stock price.

In-Line / Cautious

If results are in line but management expresses caution, the stock may experience a muted reaction as investors digest the commentary.

Miss

A miss on earnings could lead to a decline, with history showing an average drop of 0.73% in similar scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key therapies in the pipeline.
2Any new partnerships or collaborations that could enhance growth.
3Management's strategy for achieving profitability in the near term.
4Insights on market conditions affecting the biotechnology sector.
5Responses to analyst questions regarding future revenue projections.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and successfully commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the next day.

Management Promises & Guidance

Continue advancing clinical trials for key therapies.
Focus on expanding partnerships and collaborations.
Enhance operational efficiencies to drive profitability.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Roivant has shown strong EPS surprises in recent quarters, but there is uncertainty regarding revenue growth and pipeline updates.

Bull Case

If Roivant continues its trend of beating EPS estimates and provides positive updates on its drug pipeline, investor confidence could rise significantly.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates will Roivant provide regarding its drug pipeline?

The market will closely scrutinize any advancements or setbacks in the pipeline, as these can significantly impact future revenue potential.

How does management plan to achieve profitability in the upcoming quarters?

Investors are eager to hear concrete strategies for improving financial performance, especially in light of recent EPS surprises.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's potential for pipeline advancements, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Roivant has consistently surprised on EPS, indicating stronger operational performance than anticipated.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in biotechnology suggest a favorable environment for innovative therapies.

Key Risk

If the pipeline updates reveal significant progress, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Roivant's ability to leverage its innovative pipeline to drive future growth and profitability.

Bull Confirmed If

A positive update on the drug pipeline with at least one new therapy entering late-stage trials.

Bear Confirmed If

Any indication that key therapies are delayed or facing regulatory challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a nearly 10% move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations and raises guidance, history suggests a strong positive reaction, averaging a 9.09% increase in stock price.

In-Line / Cautious

If results are in line but management expresses caution, the stock may experience a muted reaction as investors digest the commentary.

Miss

A miss on earnings could lead to a decline, with history showing an average drop of 0.73% in similar scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key therapies in the pipeline.
2Any new partnerships or collaborations that could enhance growth.
3Management's strategy for achieving profitability in the near term.
4Insights on market conditions affecting the biotechnology sector.
5Responses to analyst questions regarding future revenue projections.